1887

Journal of Medical Microbiology logo

Volume 59, Issue 1

Potential use of a liposome-encapsulated mixture of lipopolysaccharide core types (R1, R2, R3 and R4) of in controlling colisepticaemia in chickens Free

Abstract

Infections caused by have an economically significant impact on the poultry industry and a non-serotype-specific vaccine appears to be the most logical method of controlling them. The core oligosaccharide-lipid A region of bacterial lipopolysaccharide (LPS) is well conserved and highly immunogenic but toxic. This study determined the possible use of a liposome-encapsulated mixture of rough LPSs of core types R1, R2, R3 and R4 in controlling infections caused by in chickens. The liposome which encapsulated the LPS consisted of egg phosphatidylcholine, bovine brain phosphatidylserine and cholesterol. As determined by amoebocyte lysate assay, incorporation of LPS into the liposome reduced the endotoxicity of LPS to 0.7 % of its initial value. When tested on a chicken macrophage cell line (HD11), liposome-incorporated LPS produced a significantly lower amount of nitric oxide (<5 μM) than that produced by free LPS (22 μM). Transcription of the genes for interleukin-1 and inducible nitric oxide synthase was lower in cells treated with liposome-incorporated LPS than in cells treated with free LPS. When chickens were immunized with 0.2 μg, 1 μg and 5 μg liposome-encapsulated mixture of LPS core types, the antibody response increased with increasing dose. When challenged with the virulent O78 strain, the birds which received 1 μg liposome-encapsulated LPS and 5 μg LPS had significantly lower lesions scores ( <0.05) and high body weight when compared with the birds in the control group as well as with the birds immunized with a suboptimal dose (0.2 μg) of liposome-encapsulated LPS.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): IFN-γ, gamma-interferon , IL-1β, interleukin-1β , iNOS, inducible nitric oxide synthase and LAL, Limulus amoebocyte lysate
SGM
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.014720-0
2010-01-01
2024-10-12
Loading full text...

Full text loading...

/deliver/fulltext/jmm/59/1/100.html?itemId=/content/journal/jmm/10.1099/jmm.0.014720-0&mimeType=html&fmt=ahah

References

  1. Arp L. H. 1980; Consequences of active or passive immunization of turkeys against Escherichia coli O78. Avian Dis 24:808–815 [CrossRef]
     [Google Scholar]
  2. Bennett-Guerrero E., McIntosh T. J., Barclay G. R., Snyder D. S., Gibbs R. J., Mythen M. G., Poxton I. R. 2000; Preparation and preclinical evaluation of a novel liposomal complete-core lipopolysaccharides vaccine. Infect Immun 68:6202–6208 [CrossRef]
     [Google Scholar]
  3. Chhibber S., Wadhwa S., Yadav V. 2004; Protective role of liposome incorporated lipopolysaccharide antigen of Klebsiella pneumoniae in a rat model of lobar pneumonia. Jpn J Infect Dis 57:150–155
     [Google Scholar]
  4. Deb J. R., Harry E. G. 1976; Laboratory trials with inactivated vaccines against Escherichia coli 078 : K80 infection in fowls. Res Vet Sci 20:131–138
     [Google Scholar]
  5. Dijkstra J., Mellors J. W., Ryan J. L., Szoka F. C. 1987; Modulation of the biological activity of bacterial endotoxin by incorporation into liposomes. J Immun 138:2663–2670
     [Google Scholar]
  6. Dijkstra J., Larrick J. W., Ryan J. L., Szoka F. C. 1988; Incorporation of LPS in liposomes diminishes its ability to induce tumoricidal activity and tumor necrosis factor secretion in murine macrophages. J Leukoc Biol 43:436–444
     [Google Scholar]
  7. Dijkstra J., Mellors J. W., Ryan J. L. 1989; Altered in vivo activity of liposome-incorporated lipopolysaccharide and lipid A. Infect Immun 57:3357–3363
     [Google Scholar]
  8. Dissanayake D. R. A., Wijewardana T. G., Gunawardena G. A., Poxton I. R. 2008; Distribution of lipopolysaccharide core types among avian pathogenic Escherichia coli in relation to the major phylogenetic groups. Vet Microbiol 132:355–363 [CrossRef]
     [Google Scholar]
  9. Elkins K. L., Stashak P. W., Baker P. J. 1987; Mechanisms of specific immunological unresponsiveness to bacterial lipopolysaccharide. Infect Immun 55:3093–3102
     [Google Scholar]
  10. Erridge C., Stewart J., Bennett-Guerrero E., McIntosh T. J., Poxton I. R. 2002; The biological activity of a liposomal complete core lipopolysaccharide vaccine. J Endotoxin Res 8:39–46 [CrossRef]
     [Google Scholar]
  11. Frommer A., Freidlin P. J., Bock R. R., Leitner G., Chaffer M., Heller E. D. 1994; Experimental vaccination of young chickens with a live, non-pathogenic strain of Escherichia coli . Avian Pathol 23:425–433 [CrossRef]
     [Google Scholar]
  12. Galanos C., Lüderitz O. 1984; Lipopolysaccharide: properties of an amphipathic molecule. In HandBook of Endotoxin. 1. Chemistry of Endotoxin pp 46–58 Edited by Rietschel E. Th. Amsterdam: Elsevier;
     [Google Scholar]
  13. Gibb A. P., Barclay G. R., Poxton I. R., di Padova F. 1992; Frequencies of lipopolysaccharide core types among clinical isolates of Escherichia coli defined with monoclonal antibodies. J Infect Dis 166:1051–1057 [CrossRef]
     [Google Scholar]
  14. Gibbs R. J., Stewart J., Poxton I. R. 2004; The distribution of, and antibody response to, the core lipopolysaccharide region of Escherichia coli isolated from the faeces of healthy humans and cattle. J Med Microbiol 53:959–964 [CrossRef]
     [Google Scholar]
  15. Green L. C., Wagner D. A., Glogowski J., Skipper P. L., Wishnok P. S., Tannenbaum S. R. 1982; Analysis of nitrate, nitrite and [15N]nitrate in biological fluids. Anal Biochem 126:131–138 [CrossRef]
     [Google Scholar]
  16. Gyimah J. E., Panigrahy B. 1985; Immunogenicity of an Escherichia coli (serotype O1) pili vaccine in chickens. Avian Dis 29:1078–1083 [CrossRef]
     [Google Scholar]
  17. Hancock I. C., Poxton I. R. 1988 Bacterial Cell Surface Techniques pp 90–93 Chichester, UK: Wiley;
     [Google Scholar]
  18. Kaiser P., Rothwell L., Galyov E. E., Barrow P. A., Burnside J., Wigley P. 2000; Differential cytokine expression in avian cells in response to invasion by Salmonella typhimurium , Salmonella enteritidis and Salmonella gallinarum . Microbiology 146:3217–3226
     [Google Scholar]
  19. Kariyawasam S., Wilkie B. N., Hunter D. B., Gyles C. L. 2002; Systemic and mucosal antibody responses to selected cell surface antigens of avian pathogenic Escherichia coli in experimentally infected chickens. Avian Dis 46:668–678 [CrossRef]
     [Google Scholar]
  20. Manthey C. L., Vogel S. N. 1994; Elimination of trace endotoxin protein from rough chemotype LPS. J Endotoxin Res 1:84–92
     [Google Scholar]
  21. Moody A., Sellers S., Bumstead N. 2000; Measuring infectious bursal disease virus RNA in blood by multiplex real-time quantitative RT-PCR. J Virol Methods 85:55–64 [CrossRef]
     [Google Scholar]
  22. Morrison D. C., Ryan J. L. 1987; Endotoxins and disease mechanisms. Annu Rev Med 38:417–432 [CrossRef]
     [Google Scholar]
  23. Müller-Loennies S., Di Padova F., Brade L., Brade H., Rietschel E. Th. 2005; Anti-endotoxin antibodies – a cross-reactive and cross-protective monoclonal antibody against a conserved epitope of Escherichia coli and Salmonella enterica . Intensivmed Notfallmed 42:27–38 [CrossRef]
     [Google Scholar]
  24. Nagaraja K. V., Emery D. A., Jordan K. A., Sivanandan V., Newman J. A., Pomery B. S. 1984; Effect of ammonia on the quantitative clearance of Escherichia coli from lungs, air sacs and livers of turkeys aerosol vaccinated against Escherichia coli . Am J Vet Res 45:392–395
     [Google Scholar]
  25. Parmentier H. K., Klompen A. L., De Vries Reilingh G., Lammers A. 2008; Effect of concurrent intratracheal lipopolysaccharide and human serum albumin challenge on primary and secondary antibody responses in poultry. Vaccine 26:5510–5520 [CrossRef]
     [Google Scholar]
  26. Peighambari S. M., Hunter D. B., Schewen P. E., Gyles C. L. 2002; Safety, immunogenicity and efficacy of two Escherichia coli cya , crp mutants as vaccines for broilers. Avian Dis 46:287–297 [CrossRef]
     [Google Scholar]
  27. Poxton I. R. 1995; Antibodies to lipopolysaccharide. J Immunol Methods 186:1–15 [CrossRef]
     [Google Scholar]
  28. Scott B. B., Barclay G. R. 1987; Endotoxin-polymyxin complexes in an improved enzyme-linked absorbent assay for IgG antibodies in blood donor sera to Gram-negative endotoxin core glycolipids. Vox Sang 52:272–280 [CrossRef]
     [Google Scholar]
  29. Trampel D. W., Griffith R. W. 1997; Efficacy of aluminum hydroxide-adjuvanted Escherichia coli bacterin in turkey poults. Avian Dis 41:263–268 [CrossRef]
     [Google Scholar]
  30. Westphal O. 1975; Bacterial endotoxin. Int Arch Allergy Appl Immunol 49:1–43 [CrossRef]
     [Google Scholar]
  31. Wigley P., Kaiser P. 2003; Avian cytokines in health and disease. Rev Bras Cienc Avic 5:1–14 [CrossRef]
     [Google Scholar]
  32. Xing Z., Schat K. A. 2000; Expression of cytokine genes in Marek's disease virus infected chickens and chicken embryo fibroblasts cultures. Immunology 100:70–71 [CrossRef]
     [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.014720-0
Loading
Potential use of a liposome-encapsulated mixture of lipopolysaccharide core types (R1, R2, R3 and R4) of Escherichia coli in controlling colisepticaemia in chickens
J. Med. Microbiol. 59, 100 (2010); https://doi.org/10.1099/jmm.0.014720-0
/content/journal/jmm/10.1099/jmm.0.014720-0
/content/journal/jmm/10.1099/jmm.0.014720-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error